People · Operator
Named in public records as an officer, director or promoter · active 2008–2025 · Other Health Care, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Wugen, Inc. | — | Other Health Care | Series D+ | $245.2M | $870.3M | 2025 |
| Eiger Biopharmaceuticals Inc | — | Biotechnology | Series A | $70.9M | $216.9M | 2008 |
Keith Vendola at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Keith Vendola on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Nina Kjellson | 1 | 11 |
| Drew Dennison | 1 | 7 |
| Niall O'Donnell | 1 | 7 |
| Bosun Hau | 1 | 6 |
| Matthew Cooper | 1 | 5 |
| Thomas Dietz | 1 | 4 |
| Peter Kiener | 1 | 4 |
| Glen Sato | 1 | 4 |
| Kevin Li | 1 | 4 |
| Paul Truex | 1 | 3 |
| Bali Muralidhar | 1 | 3 |
| Jeffrey Glenn | 1 | 2 |
| Wenjin Yang | 1 | 2 |
| Kumar Srinivasan | 1 | 2 |
| John P McKearn | 1 | 2 |
| Matthew P Cooper | 1 | 1 |
| Kevin P Li | 1 | 1 |
| David Cory | 1 | 1 |
| Drew P Dennison | 1 | 1 |
| Ed Engleman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.